Related Experiment Video
Updated: May 11, 2025
09:16
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
17.4K
Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones
1UOC of Cardiology, Policlinico Casilino, via Casilina, 1049, 00169 Rome, Italy.
Summary
New drugs like gliflozins and incretins slow chronic kidney disease (CKD) progression and reduce cardiovascular risk. Finerenone also shows promise in managing CKD and cardiovascular outcomes in diabetic patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Chronic kidney disease (CKD) is a growing global health concern with limited therapeutic options for decades.
- Progressive decline in renal function increases cardiovascular risk, leading to heart attack, stroke, heart failure, and mortality.
- Traditional CKD management, including risk factor control and renin-angiotensin-aldosterone system blockade, has shown limited efficacy.
Purpose of the Study:
- To review the impact of recent therapeutic advancements on slowing CKD progression.
- To highlight the cardiovascular benefits associated with novel CKD treatments.
- To discuss the role of new drug classes in managing CKD and associated cardiovascular risks.
Main Methods:
- Review of recent clinical trials and guideline updates concerning CKD therapies.
- Analysis of data on gliflozins, incretins, and mineralocorticoid receptor antagonists like finerenone.
- Evaluation of cardiovascular and renal outcomes in patients treated with these novel agents.
Main Results:
- Gliflozins and incretins have demonstrated efficacy in slowing CKD progression in diabetic and non-diabetic patients.
- These drug classes significantly reduce cardiovascular events and mortality.
- Finerenone, a novel mineralocorticoid receptor antagonist, has shown significant cardiovascular and renal benefits in Phase 3 trials for diabetic patients.
Conclusions:
- Novel drug classes, including gliflozins, incretins, and finerenone, represent a paradigm shift in CKD management.
- These agents offer substantial benefits in slowing renal function decline and mitigating cardiovascular risk.
- Current guidelines are evolving to incorporate these effective therapies for improved patient outcomes.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
125
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
125
01:25Antihypertensive Drugs: Direct Renin Inhibitors
440
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
440
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
401
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
401
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
136
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
136
01:24Glucagon-like Receptor Agonists
261
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
261
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305